专题发言: Randomized phase III trial of aumolertinib (HS-10296, Au) versus gefitinib (G) as first-line treatment of patients with locally advanced or metastatic nonsmall cell lung cancer (NSCLC) and EGFR exon 19 del or L858R mutations (EGFRm)
15:30-15:40
上海会场
创新药物临床研究数据专场2-Session 1
[CSCO创新专场2]